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CONSPECTUS: This Account highlights recent advances and discusses major challenges in 
investigations of cryptic (hidden) binding sites by molecular simulations. Cryptic binding sites 
are not visible in protein targets crystallized without a ligand and only become visible upon 
binding events. These sites have been shown to be druggable and might provide a rare 
opportunity to target difficult proteins. However, due to their hidden nature, they are difficult to 
find through experimental screening. Computational methods based on atomistic molecular 
simulations remain one of the best approaches to identify and characterize cryptic binding sites. 
However, not all methods are equally efficient. Some are more apt at quickly probing protein 
dynamics, but do not provide thermodynamic or druggability information, while others that are 
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able to provide such data are demanding in terms of time and resources. Here, we review the 
recent contributions of mixed-solvent simulations, metadynamics, Markov state models, and 
other enhanced sampling methods to the field of cryptic site identification and characterization. 
We discuss how these methods were able to provide precious information on the nature of the 
site opening mechanisms, to predict previously unknown sites which were used to design new 
ligands, and to compute the free energy landscapes and kinetics associated with the opening of 
the sites and the binding of the ligands. We highlight the potential and the importance of such 
predictions in drug discovery, especially for difficult (“undruggable”) targets. We also discuss 
the major challenges in the field and their possible solutions. 
 
INTRODUCTION 
In recent years, the number of biologically validated drug targets for complex diseases has 
considerably increased, especially due to large-scale genome sequencing.1,2 Unfortunately, many 
of these potential targets are considered “undruggable”, meaning they are unamenable to classic 
substrate-competitive drug discovery strategies.1 For this reason, significant efforts are put 
towards alternative strategies, including identifying allosteric ligands and characterizing hidden 
(cryptic) allosteric pockets. Cryptic binding pockets are absent in unliganded protein structures 
but open due to protein dynamics. They represent an attractive alternative to substrate-
competitive sites that have been exploited in a number of high-profile targets, including K-Ras,3,4 
an oncogene commonly found in human cancers. Despite their vast potential, the hidden nature 
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of cryptic pockets makes it difficult to use rational drug discovery approaches based on structural 
experiments or computer modeling. Indeed, most known cryptic sites have been found 
serendipitously. Even the very mechanism of the cavity opening and whether it occurs through 
an induced fit, a conformational selection, or perhaps a combination of the two, is still debated in 
the literature. However, atomistic molecular dynamics (MD) simulations provide ways to both 
model the opening of unknown cryptic sites and describe possible binding mechanisms. 
After many years of development, MD simulations are finally becoming useful in obtaining a 
detailed molecular description of protein (de)activation and ligand (un)binding. With the 
technological advancements in specialized computer architectures5 for MD simulations and 
distributed computing,6 as well as the parallelization of the MD simulation packages7 and their 
increasing use of GPUs,8 scientists are now able to reach unprecedented system sizes9 and 
timescales,10 enabling μs-long simulations on a routine basis. At the same time, both protein11-14 
and ligand15 force fields are sufficiently accurate to capture the important features of target 
dynamics and ligand binding mechanisms. Prediction of previously unknown cryptic binding 
pockets that have successively been experimentally validated to design new drugs shows how 
promising the approach is, as was the case of HIV integrase where MD simulations predicted the 
opening of a new cleft.16 Still, despite the substantial progress, conventional approaches in MD 
simulations cannot adequately sample many biologically and pharmaceutically interesting 
processes. Among such processes is the opening of buried cryptic binding sites which is a 
prerequisite for their detection. Recent studies demonstrate how this challenge can be 
successfully tackled using MD-based approaches, which offer a more dynamic picture of the 
system (compared to X-ray crystallography) and provide high-resolution structural data for drug 
design. 
 4 
In this Account, we review the recent contributions of MD simulations and modelling combined 
with experiments in understanding the nature of cryptic pockets and predicting their location. 
NATURE OF CRYPTIC POCKETS AND MECHANISMS OF THEIR FORMATION  
Similarly to all conformational changes of a target associated with ligand binding, the discussion 
on whether cryptic pockets emerge through conformational selection17,18 or induced fit19 is still 
ongoing. The former mechanism implies that the ligand’s role is to stabilize specific 
conformations that are also accessible in the unbound state. The latter mechanism proposes that 
the ligand causes the target to explore regions of the conformational space that are practically 
inaccessible to the unbound form. As discussed elsewhere,20 from the experimental point of 
view, only kinetic experiments might provide a clear distinction of the two mechanisms, as the 
binding rate in the case of conformational selection is dependent on the concentration of the 
ligand, while for the induced fit it is not. When the binding mechanism was ascertained 
experimentally, it emerged that, depending on the target, either induced fit or conformational 
selection are prevalent and in some cases both play a role.21,22 In the case of cryptic sites, an 
extensive analysis of multiple X-ray structures of proteins with validated cryptic sites performed 
by Beglov et al.23 showed that cryptic sites tend to be quite flexible which would hint towards 
conformational selection, but they are also almost always close to binding energy hot spots, often 
exploited by the bound ligands, suggesting that an induced fit component is also important for 
binding. This finding is in agreement with our simulations of the cryptic pocket found at the 
interface between α-helices H11 and H12 of TEM1 β-lactamase. Long timescale simulations of 
the system have detected this cryptic pocket in the absence of a ligand and suggested roles for 
both induced fit and conformational selection.24 The role of conformational selection was 
supported further by subsequent experiments that detected the cryptic pocket in the absence of 
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ligand.25 Enhanced sampling simulations of small fragments binding to the pocket are also 
consistent with a picture in which large fluctuations lead to the opening of the pocket 
(conformational selection) which are then stabilized by small molecules wedging between the 
helices (induced fit).26 
Analysis of ~90 available crystal structures harboring cryptic sites showed that the main 
conformational changes associated with their opening are linked to: lateral chain rotation, loop 
movements, secondary structure changes, and interdomain motions (Figure 1).23,27 Cryptic 
pockets have been also found to play a role at flexible protein-protein interfaces.28  
Thus, cryptic pocket opening is associated with conformational changes of the target and the 
extent of such change plays a role in the operative definition of crypticity (i.e., a site “being 
cryptic”).   The operative definition of crypticity is based on whether the pocket is present or 
visible in the apo structure and is typically a continuous measure based on measures of pocket 
exposure or steric clash with the ligand. Thus, depending on the chosen threshold, a pocket can 
be considered cryptic or not, and even sites contiguous with the catalytic pocket can end up 
being labelled as cryptic.  
Algorithms for the detection and analysis of pockets per se (including their transient formation), 
are thus instrumental to distinguish and identify the cryptic ones. To this aim, a number of pocket 
analysis tools have been developed by the community. Tools such as Fpocket,29 Epock,30 
POVME,31 TRAPP,32 and Nanoshaper33 are able to detect and/or analyse both stable and 
transient pockets. When the pockets are not particularly buried and the opening mechanism is 
mainly conformational selection, these tools can successfully detect the presence of cryptic 
pockets in the trajectories of the unliganded target. 
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Finally, the mere detection of a cryptic pocket does not make a target tractable per se. The newly 
found pocket needs to be ligandable. Having a cryptic pocket that is close to a binding hotspot 
and can accommodate chemically diverse fragments increases the chances that they are 
ligandable.23  Some pocket analysis algorithms and mixed solvent simulations also provide an 
estimate of the pocket ligandability.29,32  
An allosteric connection of the remote pocket to the catalytic site or other functionally important 
sites is also needed for its druggability. As allosteric connections are bidirectional, an MD-based 
analysis of allosteric signal propagation from and to the active site of a target can be used to 
discover previously unknown binding sites. For instance, in the case of Hsp90, such a method 
was used to characterize the allosteric “hot spots” involved in interdomain communication 





Figure 1. Illustration of common structural changes associated with cryptic binding site 
formation. a. Side chain rearrangements as shown in IL2 (apo: 1M47_A, holo: 1PY2_D), b. loop 
movements in NPC2 (apo: 1NEP_A, holo: 2HKA_C), c. secondary structure changes like the 
partial helix unfolding in LfrR (apo: 2WGB_A, holo: 2V57_A), and d. interdomain motions in 
EF-TU (apo: 1EXM_A, holo: 1HA3_B). Apo structures are show in gray and holo structures in 
slate blue, while red arrows highlight the main structural changes. 
MIXED-SOLVENT MOLECULAR DYNAMICS SIMULATIONS 
To facilitate the exploration of cryptic binding sites, one of the approaches based on MD 
simulations relies on the use of small probes mixed with water molecules that help open and 
stabilize cryptic pockets which are often hydrophobic. These simulations are known as mixed-
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solvent MD simulations.36-39 Probes that were successfully tested were either readily miscible 
with water (e.g., acetic acid, isopropanol, or resorcinol),36,40 or quite hydrophobic (e.g. 
benzene)26,41 and in such cases a repulsive potential is necessary to prevent the probes from 
clustering.37,42 Mixed-solvent MD simulations have been successfully used on a number of 
targets to characterize active and allosteric sites and are relatively simple to set up.28,36-38,43 
Schmidt et al. tested the performance of various co-solvent compositions on seven diverse 
targets with known cryptic sites and reported that a composition of 90% water and 10% phenol 
was the most effective in opening the cavities without unfolding the proteins.44 The pocket 
occupancy and fragment residence time obtained from  mixed-solvent MD simulations can also 
provide druggability estimates, which is important to assess the feasibility of targeting a pocket 
with small molecules.16,36 However, their application to cryptic pockets detection still requires 
substantial sampling of the system. For instance, we showed that, in the case of the cryptic 
pocket of TEM1 β-lactamase, 6 different hydrophobic ring probes were able to open the cryptic 
pocket only in a few 100-ns-long simulations out of 32 that we ran for each of the probes. 
Extending the mixed-solvent simulations with benzene to more than 1 μs resulted in the opening 
of the pocket in 1/3 of the simulations.26 Sampling problems also affect the ability of mixed-
solvent MD simulations to identify deeply buried cryptic pockets as their exploration relies on 
the diffusion of probe molecules around the protein surface and/or overcoming high energy 
barriers. An additional problem with mixed solvent MD is the risk of unfolding the protein with 
hydrophobic probes44 which in some cases can be circumvented through a carefully selected set 
of position/distance restraints.41  
COLLECTIVE-VARIABLE-DEPENDENT ENHANCED SAMPLING METHODS 
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When conventional MD simulations prove ineffective in sampling the event of interest, enhanced 
sampling methods can be used. Such techniques can be practically divided based on their 
dependence on collective variables (CV). In the case of CV-dependent methods, like 
metadynamics,45,46 umbrella sampling,47 and steered MD,48 the process of interest is 
approximated through CVs, i.e. the functions of system’s coordinates that can be as simple as a 
distance between two atoms or as complex as a contact map describing an active state of a 
protein. Unfortunately, choosing suitable CVs can be far from straightforward which is why 
these choices are often guided by experimental data. Recently, metadynamics was successfully 
applied to investigate the binding mechanism of SSR128129E (SSR), a newly developed 
inhibitor of fibroblast growth factor receptor 1 (FGFR1).49,50 This receptor tyrosine kinase arose 
as a potential anticancer drug target due to its involvement in numerous essential cellular 
processes, such as blood vessel formation. SSR was initially discovered through high-throughput 
screening and its binding location was narrowed down to the extracellular D3 Ig-like domain, but 
the exact binding site eluded both X-ray crystallography and NMR due to the disordered nature 
of the domain. Using a range of CVs that describe not only the binding process, but also the 
folding of the domain, the authors were able to capture inhibitor’s reversible binding to a hidden 
pocket formed through the elongation of a small α-helix in the D3 domain. The observed binding 
mechanism was further confirmed with a mutational analysis and subsequently used to design 
more potent inhibitors. Despite this success story, using CV methods based on geometric criteria 
to systematically predict cryptic binding sites is challenging as it is difficult to find a set of 
parameters that adequately captures the complexity of the cryptic binding pocket formation in 
the absence of previous information on the location and nature of the pocket.26 
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The JEDI methodology is a CV-based approach that overcomes these limitations and allows to 
bias sampling towards protein conformations of favorable druggability.51 It uses a 3D grid 
overlapped on a region of interest on a protein surface to determine the location of putative 
pockets, and calculates a druggability score, i.e., a quantification of how adequate those pockets 
are to accommodate a small organic molecule. This druggability scoring was inspired by 
structural bioinformatics methodologies trained on datasets of X-ray crystallography-derived 
binding sites,52,53 with the important difference that the druggability estimator was designed to be 
smooth and continuously differentiable with respect to protein atomic Cartesian coordinates. 
This enables the use of the JEDI score as a collective variable for biased MD simulations. 
Therefore, a typical workflow to seek cryptic pockets with JEDI involves working out the 
druggability score of a protein region covered by a manually placed 3D grid, and subsequently 
carrying out biased MD simulations to encourage the protein to adopt new conformations that 
increase (or decrease) the initial druggability score. Because the estimator scores favorably 
hydrophobic cavities suitably sized to accommodate a small molecule, the application of JEDI to 
a protein region that does not contain a pocket will encourage spontaneous sampling of a cavity 
without requiring a priori knowledge of which residues must undergo a conformational change 
to reveal a cryptic pocket. The process can be very rapid, requiring only a few nanoseconds of 
MD simulation (Figure 2). Current drawbacks of the first version of the algorithm include the 
relatively expensive cost of the CV, making long timescale simulations difficult, and support for 
implicit solvent simulations only. The JEDI CV can also suffer from degeneracy, leading to the 
biased simulations becoming stuck in an alternative conformational state that may not accurately 
describe the cryptic pocket owing to the approximate nature of the druggability estimator.  
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Figure 2. a. Representative snapshot from the most populated cluster of an equilibrium MD 
simulation of apo VHL. The binding-site lining residues (highlighted in slate blue) adopt a 
collapsed conformation with low druggability score b. A JEDI-biased MD simulation of apo 
VHL has rearranged the binding-site lining residues in a druggable conformation. In both panels 
an overlay of the crystallographic structure of a VHL ligand is displayed in orange sticks. Red 
arrows highlight the main structural changes. 
COLLECTIVE-VARIABLE-INDEPENDENT ENHANCED SAMPLING METHODS 
One of the most commonly used CV-independent enhanced sampling methods is parallel 
tempering (i.e., temperature replica exchange MD)54 where several replicas of the system are run 
at the same time, but at different temperatures. At regular intervals, an exchange between the 
neighboring replicas is attempted and either accepted or rejected based on the Metropolis 
criterion. The method is usually quite effective (albeit computationally expensive as it requires a 
large number of replicas to span a wide range of temperatures) in studying protein 
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conformational landscapes. However  when it came to studies of cryptic binding sites, it was 
unable to open the pockets in the targets that were tested, even at temperatures of 400 K.26 This 
is probably due to the entropic nature of the energy barriers involved in pocket opening.26 A 
different approach, based on non-equilibrium MD simulations (rotamerically induced 
perturbations or RIP) was proposed by Kokh et al. to initiate large-scale protein movements and 
sample cryptic sites.55 This approach proved useful for a rapid evaluation of pocket flexibility. 
However, RIP is not able to predict folding of protein segments, nor the kinetics or 
thermodynamics associated with the protein motions.56  
Considering the hydrophobic nature of cryptic binding pockets, Oleinikovas et al. devised a 
method in which they sample water interactions through scaled Hamiltonians (SWISH).26 The 
method is based on a Hamiltonian replica exchange approach and, instead of altering the 
temperature of the replicas as in parallel tempering, it changes the interaction of apolar carbons 
and sulfurs with water oxygen. This renders the protein less hydrophobic at higher replicas and 
allows for more effective exploration of cryptic binding sites compared to conventional MD 
simulations. The method was tested on a range of pharmaceutically relevant targets, such as β-
lactamase, IL2, and PLK1 in the initial study,26 and NPC2, LfrR, p38α, and hPNMT in the 
follow-up study.41 SWISH was able to successfully detect known cryptic binding sites in these 
proteins, typically within 1 μs of of sampling time with 6-8 replicas. When combined with 
probes which stabilized the open cryptic binding sites, it became apparent that the formation 
mechanism of cryptic binding pockets typically involves both conformational selection and 
induced fit. However, the approach combining SWISH with probes suffers from the same 
drawbacks as mixed-solvent simulations where the proteins can become denatured when the 
selected probes are hydrophobic in nature. Such behavior is even more pronounced in SWISH 
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simulations where the protein is already pushed towards more hydrophilic states. A way to 
prevent the protein from unfolding is either through a more conservative set of scaling factors or 
by using a contact-map restraint41 which is applied on a small set of relevant contacts away from 
the site of interest that essentially keeps the secondary structure elements folded. Further 
iterations of the method involve a more targeted approach where only the interactions of 
hydrophobic residues with water are scaled which would hopefully also reduce the protein 
unfolding and rendering the contact-map restraint unnecessary. Another advantage of SWISH is 
that it can be easily combined with other enhanced sampling methods, such as metadynamics, if 
the cryptic binding pocket of interest forms through a more complex conformational change, as 
was the case of FGFR1.50 
MARKOV STATE MODELS (MSMs) 
MSMs are a powerful mean to integrate many independent simulations into a map of protein’s 
conformational space that captures long-timescale events far beyond the reach of any individual 
simulation.57 These methods were originally developed to study protein folding mechanisms.58 
However, they have since proved extremely effective in a wide variety of settings.59 
Inspired by the conformational selection model, MSMs were first applied to the apo TEM1 β-
lactamase enzyme introduced above.24 The resulting model successfully identified the cryptic 
pocket between helices 11 and 12, supporting a role for conformational selection in the opening 
of such pockets. A second model built in the presence of a known ligand for this cryptic site also 
demonstrated a role for induced fit, consistent with previous applications of MSMs to other 
protein-ligand binding processes60 that revealed an interplay between conformational selection 
and induced fit. In addition to recapitulating the known cryptic pocket, subsequent analysis of the 
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β-lactamase MSM revealed at least two additional cryptic pockets.25 To test this prediction, an 
experimental thiol labeling assay was applied to detect the exposure of buried residues upon 
pocket opening. The results confirmed the two newly predicted pockets and a role for 
conformational selection in the opening of all three sites.25 Since then, MSMs have been applied 
to hunt for cryptic pockets in a number of other proteins.61-63 New adaptive sampling algorithms 
have also been developed to reduce the computational cost of building such models.64 Strikingly, 
these approaches have revealed yet another cryptic pocket that is common to multiple β-
lactamase families (Fig. 3).65 Experimental tests have confirmed the existence of this pocket and 
demonstrated that it exerts more potent allosteric control over enzymatic activity than the 
previously identified pockets.65,66 Applications to multiple related proteins are also beginning to 
reveal the sequence-dependence of the probabilities of potentially druggable sites.39,66,67 
 
Figure 3. A new cryptic pocket in TEM1 β-lactamase that was discovered with MSMs and 
subsequently confirmed by experimental tests. An open structure (blue) is overlaid on the apo 
crystal structure (gray) with the key catalytic serine (S70) in sticks (orange). The red arrow 
highlights a large loop motion that creates a cryptic pocket adjacent to the active site. 
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Having succeeded in detecting cryptic pockets, MSMs are now actively being used to 
intentionally target these sites with small molecules. Hypothetically, this could be achieved by 
taking an individual structure with an open cryptic pocket and applying existing rational drug 
design tools. However, more effective approaches could systematically take advantage of all the 
conformational diversity an MSM captures. One proposal for achieving this end, called 
Boltzmann docking,67 works by docking a library of compounds against a representative 
structure from each state in an MSM and then, using the equilibrium probabilities of those states, 
to calculate a Boltzmann-weighted average docking score. Boltzmann docking is related to 
ensemble docking.68 The primary difference is that Boltzmann docking uses the equilibrium 
probabilities of each state instead of treating all conformations equally. In doing so, Boltzmann 
docking automatically favors compounds that bind to higher probability states over compounds 
that bind higher-energy (i.e. lower probability) states where a greater penalty has to be paid to 
stabilize the conformation. Boltzmann docking has been successfully applied to find new 
allosteric modulators of TEM1 β-lactamase, including both inhibitors and activators.69 The 
discovery of activators is intriguing as it suggests the potential for enhancing desirable functions 
in other settings, e.g., to counteract the deleterious effects of a disease-causing mutation. 
OTHER COMPUTATIONAL APPROACHES 
Despite the aforementioned advances in computer software and hardware, MD simulations still 
require a significant amount of computational resources and time to adequately sample protein 
conformational landscapes. Thus, the appeal of inexpensive computational methods that rapidly 
predict cryptic binding sites is evident. Cimermancic et al. recently curated a data set of apo and 
holo protein pairs from the PDB harboring cryptic binding sites (composed of ~90 proteins) 
which they used to build a machine learning model (CryptoSite) to predict such sites in proteins 
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considered undruggable.27 The authors initially used over 50 features they deemed potentially 
relevant for the cryptic binding site prediction, however, only three of them proved to be 
statistically significant - the average pocket score calculated for conformations obtained from 
MD simulations that rely on a simplified energy landscape, the sequence conservation of the site, 
and the likelihood of binding small-molecule fragments. While the approach is certainly fast and 
remarkably accurate for the testing set, it drew criticism due to the overall small size of the 
training and testing sets, as well as the use of a single apo structure in each pair which can lead 
to an overestimation of the site’s crypticity as the pocket could be quite apparent in other apo 
structures.23,70 Beglov et al. expanded the original CryptoSite data set by including these 
structures and analyzed the new set using their own tools (FTMap and FTFlex).23 The authors 
showed that cryptic binding sites in apo structures typically have a strong binding hot spot in 
their vicinity and that they exhibit an above-average flexibility. It should be, however, noted that 
the analysis of X-ray structures has its limitations due to their static nature and the presence of 
crystal contacts that can introduce a range of artifacts.71 Efforts are also underway to identify 
cryptic pockets using Rosetta-based Monte Carlo sampling of the conformational space.72 
PERSPECTIVES 
The past few years have seen the successful execution of a number of proof-of-concept studies 
that have demonstrated it is possible to computationally identify cryptic pockets and then target 
them with small molecules. Methods based on MD simulations combined with algorithms for the 
detection of pockets, mixed solvents, enhanced sampling, and Markov state models are 
increasingly effective in sampling and identifying cryptic pockets, providing high-quality 
structural models for the design of novel drug-like compounds. Some of these methodologies, 
namely CV-based enhanced sampling methods and MSMs, are also able to provide accurate 
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estimates of the free energy penalty associated with the opening of the pockets, while 
simulations with mixed solvents and fragments provide precious information on the ligandability 
of the newly discovered sites. As many cryptic pockets are allosteric, i.e., remote from known 
functional sites, an important question is whether binding of a small molecule at a cryptic pocket 
has a functional effect on the protein. Even in this case, methods to characterize allosteric 
communication networks based on simulations can provide solid predictions. Looking ahead, as 
many new cryptic pockets are predicted by simulations, experimental validation becomes a 
crucial bottleneck in the search for cheaper solutions than the ones currently used. Machine 
learning approaches predict that a vast number of potential drug targets in the human genome 
harbor cryptic sites. It will be exciting to see how many of those, particularly in validated drug 
targets that small molecule drugs have yet to be discovered for, can be targeted by leveraging the 
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